Aura Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
AURA$7.66+16.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $31,693 | $41,063 |
| Marketable securities | 119,401 | 185,087 |
| Restricted cash and deposits | — | 19 |
| Prepaid expenses and other current assets | 9,529 | 5,625 |
| Total current assets | 160,623 | 231,794 |
| Restricted cash and deposits, net of current portion | 768 | 768 |
| Right-of-use assets - operating lease | 17,379 | 18,854 |
| Other long-term assets | 518 | 509 |
| Property and equipment, net | 3,215 | 3,150 |
| Total Assets | $182,503 | $255,075 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | 2,304 | 1,787 |
| Short-term operating lease liability | 3,149 | 2,687 |
| Accrued expenses and other current liabilities | 9,460 | 7,883 |
| Total current liabilities | 14,913 | 12,357 |
| Long-term operating lease liability | 15,620 | 16,870 |
| Total Liabilities | 30,533 | 29,227 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.00001 par value, 150,000,000 authorized at December 31, 2024 and December 31, 2023, and 49,998,279 and 49,350,788 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 525,934 | 512,617 |
| Accumulated deficit | (374,227) | (287,308) |
| Accumulated other comprehensive income | 263 | 539 |
| Total Stockholders’ Equity | 151,970 | 225,848 |
| Total Liabilities and Stockholders’ Equity | $182,503 | $255,075 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.